TY - JOUR
T1 - A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease
AU - Bauer, Martin
AU - Langer, Oliver
AU - Dal-Bianco, Peter
AU - Karch, Rudolf
AU - Brunner, Martin
AU - Abrahim, Aiman
AU - Lanzenberger, Rupert
AU - Hofmann, Andrea
AU - Joukhadar, Christian
AU - Carminati, Paolo
AU - Ghirardi, Orlando
AU - Piovesan, Paola
AU - Forloni, Gianluigi
AU - Corrado, Mario E.
AU - Lods, Nadège
AU - Dudczak, Robert
AU - Auff, Eduard
AU - Kletter, Kurt
AU - Müller, Markus
PY - 2006/9
Y1 - 2006/9
N2 - This work describes a microdosing study with an investigational, carbon 11-labeled antiamyloid drug, 1,1′-methylene-di-(2-naphthol) (ST1859), and positron emission tomography (PET) in healthy volunteers (n = 3) and patients with Alzheimer's disease (n = 6). The study aimed to assess the distribution and local tissue pharmacokinetics of the study drug in its target organ, the human brain. Before PET studies were performed in humans, the toxicologic characteristics of ST1859 were investigated by an extended single-dose toxicity study according to guidelines of the Food and Drug Administration and European Medicines Agency, which are relevant for clinical trials with a single microdose. After intravenous bolus injection of 341 ± 21 MBq [11C]ST1859 (containing
AB - This work describes a microdosing study with an investigational, carbon 11-labeled antiamyloid drug, 1,1′-methylene-di-(2-naphthol) (ST1859), and positron emission tomography (PET) in healthy volunteers (n = 3) and patients with Alzheimer's disease (n = 6). The study aimed to assess the distribution and local tissue pharmacokinetics of the study drug in its target organ, the human brain. Before PET studies were performed in humans, the toxicologic characteristics of ST1859 were investigated by an extended single-dose toxicity study according to guidelines of the Food and Drug Administration and European Medicines Agency, which are relevant for clinical trials with a single microdose. After intravenous bolus injection of 341 ± 21 MBq [11C]ST1859 (containing
UR - http://www.scopus.com/inward/record.url?scp=33748157070&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748157070&partnerID=8YFLogxK
U2 - 10.1016/j.clpt.2006.05.007
DO - 10.1016/j.clpt.2006.05.007
M3 - Article
C2 - 16952488
AN - SCOPUS:33748157070
VL - 80
SP - 216
EP - 227
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
SN - 0009-9236
IS - 3
ER -